The supplementary material comprises figures S1-S7 and supplementary tables 1-2.
Related to Figure 1 a, b Endotoxin-free recombinant human α-synuclein were incubated for 14 d. At the indicated time points, s mall aliquots were analyzed using thioflavin T binding assays (a) and observed under electron microscopy (b). c, d Astrocytes isolated from non-Tg (nTg) and LRRK2-GS (GS) mice were treated with tunicamycin (T u) for 24-48 h. Expression levels of the indicated mRNAs (c) and proteins (d) were analyzed by real-time q PCR and Western blotting, respectively. e, f Representative images and summary data showing TUNEL st aining (e) and live/dead staining (f) of non-Tg and LRRK2-GS astrocytes 72 h after treatment with Tu. All d ata are presented as means ± SD of three independent experiments (*p < 0.05). Figure 2 a Confocal images of endogenous LRRK2 and calnexin in astrocytes isolated from non-Tg and LRRK2-GS mice. Magnification of insets in A to show the localization of LRRK2 in nuclear envelope (a') and peri pheral ER regions (a''). b Western blot of LRRK2 in ER-enriched fractions from non-Tg and LRRK2-GS astrocytes incubated with or without proteinase K (PK). LRRK2 was detected using antibodies against th e C-or N-terminal of LRRK2 (N241A/34 and N138/6, respectively). Arrowheads indicate non-specific ba nds, and arrow indicates LRRK2. Figure 4 a Non-Tg and LRRK2-GS astrocytes were treated with α-synuclein (α-Syn) with or without CyPPA, a posit ive modulator of the SK2 channel. The indicated protein levels were analyzed by Western blotting. Crossh atching denotes the cleaved caspase-12 band. b Non-Tg and LRRK2-GS astrocytes were treated with α-Syn and immunoprecipitated with an antibody against SERCA, followed by immunoblot analysis with the i ndicated antibodies. c C2 myoblasts (C2), astrocytes (Ast) and primary neurons (Neu) were incubated wit h or without Tu for 24 h, after which levels of the indicated proteins were analyzed by Western blotting. 5'-GUAACUCUUUGGCUAUUGU-3'
